Eli Lilly Expands Obesity Access As Oral GLP-1 Data Shape Growth Story [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Eli Lilly (NYSE:LLY) has launched its Employer Connect platform to help U.S. companies expand access to obesity medicines for their employees. The company also released positive phase 3 results for its oral GLP-1 drug candidate orforglipron in type 2 diabetes, in a head to head trial against another oral treatment. These moves come as Eli Lilly challenges Novo Nordisk in the fast growing market for obesity and oral weight loss medicines. Eli Lilly, trading at around $1,003.57, sits at the center of investor attention given the rising focus on obesity and diabetes treatments. The stock is up 8.7% over the past year and has risen strongly over the past 3 and 5 years. This indicates that expectations around its obesity and diabetes pipeline are already significant. For investors, the new Employer Connect platform and orforglipron data relate to how far and how fast Lilly can broaden access
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- GLP-1 drugs linked to lower addiction risk, study finds [USA TODAY]USA TODAY
- GLP-1 Receptor Agonist (Trulicity, Wegovy, Ozempic, Mounjaro) Market Trends Analysis Report 2026 [Yahoo! Finance]Yahoo! Finance
- Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? [Yahoo! Finance]Yahoo! Finance
- Third Annual Bio-IT World Venture, Innovation & Partnering Conference Returns to Boston May 19 [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (LLY) had its "overweight" rating reaffirmed by Morgan Stanley.MarketBeat
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 2/19/26 - Form 4
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- LLY's page on the SEC website